Trial results
$AVIR — BEM/RZR (bemnifosbuvir/ruzasvir)
Atea Pharmaceuticals, Inc. (AVIR) BEM/RZR (bemnifosbuvir/ruzasvir): trial results in Hepatitis C virus (HCV) infection, 2027.
The catalyst
"Topline results from C-FORWARD, Atea's Phase 3 trial in patients with HCV outside of North America, are anticipated in early 2027."
— Atea Pharmaceuticals, 8-K filed 2026-11-09 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
AVIR-BEMRZRBEMNIF-2026- Company
- Atea Pharmaceuticals, Inc.
- Kind
- Trial results
- Indication
- Hepatitis C virus (HCV) infection
- Window
- 2027-01-01 – 2027-04-30
- Status
- slate
The bar
No bar has been published for this event yet.
Verdicts
Sealed with the bar. Any verdict for this event reaches this page on 2027-05-30; subscribers get it on the day.